



04-21-03

1646

Practitioner's Docket No. MWH-0303US2

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Drysdale et al.  
Application No.: 09/811,285  
I.A. Filing Date: April 13, 2000  
I.A. No.: PCT/US00/10125

Group Art Unit: 1646  
Examiner: Joseph F. Murphy

#14

FOR: ASSOCIATION OF BETA2-ADRENERGIC RECEPTOR HAPLOTYPES WITH DRUG  
RESPONSE

RECEIVED

APR 23 2003

Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
AFTER MAILING OF FIRST OFFICE ACTION BUT WITHIN THREE MONTHS OF A  
COMMUNICATION FROM A FOREIGN PATENT OFFICE (37 C.F.R. §1.97(c) & (e))

Enclosed herewith please find:

1. Identification of Time of Filing the Accompanying Information Disclosure Statement
2. Supplemental Information Disclosure Statement by Applicant Form PTO/SB/08B(1 page)
3. Copy of Listed Reference Accompanying Statement (2-Total)
4. Self-addressed stamped postcard

It is believed that no fee is required, but if that is incorrect you are hereby authorized to debit Deposit Account No. 50-1293 for any deficiency

## CERTIFICATION UNDER 37 C.F.R. SECTION 1.10\*

(Express Mail label number is mandatory.)  
(Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on April 18, 2003 (date), in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. Section 1.10, Mailing Label Number EL533974842US addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

Adam Gerbik  
(type or print name of person mailing paper)  
Adam Gerbik  
Signature of person mailing

Date: 4/18/2003

Melodie W. Henderson  
Signature of Practitioner

Reg. No.: 37,848  
Tel. No.: 203-786-3421  
Customer No.: 25106

Melodie W. Henderson  
Genaissance Pharmaceuticals, Inc.  
Five Science Park  
New Haven, CT 06511





Practitioner's Docket No. MWH-0303US2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Drysdale et al.  
Application No.: 09/811,285  
I.A. Filing Date: April 13, 2000  
I.A. No.: PCT/US00/10125

Group Art Unit No.: 1646  
Examiner: Joseph F. Murphy

FOR: ASSOCIATION OF BETA2- ADRENERGIC RECEPTOR HAPLOTYPES  
WITH DRUG RESPONSE

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
APR 23 2003  
TECH CENTER 1600/2900

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Each item of information contained in the supplemental information disclosure statement submitted herewith was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made by Applicants, or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Respectfully submitted,  
GENAISSANCE PHARMACEUTICALS, INC.

Date: 4/15/03  
Tel. No. 203-786-3421  
Fax No. 203-776-2788  
Registration No. 37,848  
m.henderson@genaisance.com

By: Melodie W. Henderson  
Melodie W. Henderson



25106

PATENT TRADEMARK OFFICE